Xenon Announces Azetukalner NDA Submission to FDA for Focal Seizures and Provides Update on Psychiatry Clinical Program
Xenon Pharmaceuticals has submitted a New Drug Application for azetukalner in focal seizures to the FDA, based on positive data from the Phase 2b X-TOLE and Phase 3 X-TOLE2 studies in which all four doses showed statistically significant reductions in monthly seizure frequency versus placebo. Separately, Xenon has voluntarily paused enrollment of new patients in its MDD and bipolar depression studies after an analysis of neuropsychiatric adverse events; already-enrolled participants remain on study, and the company says the events are consistent with azetukalner's known safety profile but had not been seen in the Phase 2 X-NOVA study.
Key figures
- Xackt enrollment target
- 160
- Xnova2 patients enrolled
- 360
- Xnova2 target enrollment
- 450
- Xtole3 enrollment target
- 360
- Patient years safety data
- 1500
- Psychiatry topline timing
- Q1 2027
- Xnova2 enrollment pct of target
- 80%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.